Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuel Mitry

Showing results (61-70 of 114) with videos related to

Pageof 12
Sort By:
Endocrine-Related Cancer|December 20, 2013
Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the artLouis de Mestier, Clarisse Dromain, Gaspard d'Assignies, et al.
Gastroenterologie Clinique Et Biologique|March 10, 2007
Chemotherapy as initial treatment of locally advanced unresectable pancreatic cancer: a valid option?Jean-Baptiste Bachet, Emmanuel Mitry, Céline Lepère, et al.
Gastroenterologie Clinique Et Biologique|January 8, 2008
Risk of venous thrombosis in patients with pancreatic adenocarcinomaEmmanuel Mitry, Raffic Taleb-Fayad, Antoine Deschamps, et al.
Gastroenterologie Clinique Et Biologique|March 1, 2006
Longitudinal quality of life study in patients with metastatic gastric cancer. Analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncologyFranck Bonnetain, Olivier Bouché, Thierry Conroy, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2014
Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trialEmmanuel Mitry, Thomas Walter, Eric Baudin, et al.
European Journal of Gastroenterology & Hepatology|November 2, 2012
Colorectal neuroendocrine carcinomas and adenocarcinomas share oncogenic pathways. A clinico-pathologic study of 12 casesRaymond Karkouche, Jean-Baptiste Bachet, Jeremy Sandrini, et al.
Lung Cancer (Amsterdam, Netherlands)|October 27, 2019
Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancerMaurice Pérol, Nick Pavlakis, Evgeny Levchenko, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 7, 2011
Relapse factors for ileal neuroendocrine tumours after curative surgery: a retrospective French multicentre studyCatherine Le Roux, Catherine Lombard-Bohas, Christelle Delmas, et al.
Annals of Gastroenterology|November 29, 2023
Outcome of nonfunctioning pancreatic neuroendocrine tumors after initial surveillance or surgical resection: a single-center observational studyMariola Marx, Fabrice Caillol, Sébastien Godat, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 9, 2014
Management of patients over 80 years of age treated with resection for localised colon cancer: results from a French referral centreAstrid Lièvre, Valérie Laurent, Tristan Cudennec, et al.
Pageof 12

Showing results (61-70 of 114) with videos related to

Sort By:
Pageof 12
Endocrine-Related Cancer|December 20, 2013
Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the artLouis de Mestier, Clarisse Dromain, Gaspard d'Assignies, et al.
Gastroenterologie Clinique Et Biologique|March 10, 2007
Chemotherapy as initial treatment of locally advanced unresectable pancreatic cancer: a valid option?Jean-Baptiste Bachet, Emmanuel Mitry, Céline Lepère, et al.
Gastroenterologie Clinique Et Biologique|January 8, 2008
Risk of venous thrombosis in patients with pancreatic adenocarcinomaEmmanuel Mitry, Raffic Taleb-Fayad, Antoine Deschamps, et al.
Gastroenterologie Clinique Et Biologique|March 1, 2006
Longitudinal quality of life study in patients with metastatic gastric cancer. Analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncologyFranck Bonnetain, Olivier Bouché, Thierry Conroy, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2014
Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trialEmmanuel Mitry, Thomas Walter, Eric Baudin, et al.
European Journal of Gastroenterology & Hepatology|November 2, 2012
Colorectal neuroendocrine carcinomas and adenocarcinomas share oncogenic pathways. A clinico-pathologic study of 12 casesRaymond Karkouche, Jean-Baptiste Bachet, Jeremy Sandrini, et al.
Lung Cancer (Amsterdam, Netherlands)|October 27, 2019
Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancerMaurice Pérol, Nick Pavlakis, Evgeny Levchenko, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 7, 2011
Relapse factors for ileal neuroendocrine tumours after curative surgery: a retrospective French multicentre studyCatherine Le Roux, Catherine Lombard-Bohas, Christelle Delmas, et al.
Annals of Gastroenterology|November 29, 2023
Outcome of nonfunctioning pancreatic neuroendocrine tumors after initial surveillance or surgical resection: a single-center observational studyMariola Marx, Fabrice Caillol, Sébastien Godat, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 9, 2014
Management of patients over 80 years of age treated with resection for localised colon cancer: results from a French referral centreAstrid Lièvre, Valérie Laurent, Tristan Cudennec, et al.
Pageof 12